The discovery and optimization of a novel series of GPR142 agonists are described. These led to the identification of compound 21 (LY3325656), which demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. Compound 21 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2019.126857 | DOI Listing |
Publication Analysis
Top Keywords
gpr142 agonist
8
discovery ly3325656
4
ly3325656 gpr142
4
agonist suitable
4
suitable clinical
4
clinical testing
4
testing human
4
human discovery
4
discovery optimization
4
optimization novel
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!